Document:

Private Label Supply Agreement

 Exhibit 10.20 
 CONFIDENTIAL TREATMENT REQUESTED 
 PRIVATE LABEL SUPPLY AGREEMENT 
 THIS PRIVATE LABEL SUPPLY AGREEMENT (“Agreement”) is entered into as of July 1, 2006 (the “Effective Date”), by
and between IsoTis OrthoBiologics, Inc., a Washington corporation (“Supplier”) and Alphatec Spine, Inc., a California corporation (“Distributor”). 
 R E C I T A L S 
 WHEREAS, Supplier is engaged in the business of bone
regeneration technologies including the development, production and distribution of proprietary natural and synthetic bone graft substitutes. 
 WHEREAS, Distributor is engaged in the business of designing, manufacturing and selling products and instruments to treat diseases and injuries to the human skeletal system. 
 WHEREAS, Distributor desires to acquire and distribute Supplier’s DynaGraft® II Demineralized Bone Matrix Putty and Gel (each a “DBM” and collectively the “DBMs”)
under the Distributor’s own respective brand names, and Supplier is willing to supply such DBMs to Distributor, in accordance with the terms and conditions set forth in this Agreement. 
 AGREEMENT 
 NOW, THEREFORE, in consideration of the mutual covenants and
agreements contained herein and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties agree as follows: 
  

	 	1.	Manufacture and Supply. 

 (a) General. During
the term of this Agreement, Supplier shall produce, package and supply the DBMs to Distributor, and Distributor shall acquire the DBMs from Supplier, pursuant to the terms and provisions set forth herein. Under this Agreement, Distributor engages
Supplier as a technology and value added tissue-processing provider. The buying and selling of human tissue is generally prohibited by law, and any fees associated with providing human tissue for implantation are the reasonable payment for removal,
processing, disposal, preservation, quality control, packaging and storage of such tissue plus the application of technologies and operating costs associated with providing such technologies, to which human tissue has been added, for implantation
and other surgical uses. 
 (b) Specifications. The DBMs shall be final packaged by Supplier and sterile when delivered. Supplier
shall produce the DBMs to the specifications relating to the manufacture and quality of the DBMs set forth on Schedule 1, as the same may be modified from time to time, (the “Specifications”). 

 (c) Packing and Brand Names. The DBMs shall be finally packaged by Supplier using the trade names
and artwork specified on Schedule 2, as the name may be modified from time to time (the “Private Label Brands”). Supplier’s name shall not appear on labels unless required by law and, if required by law, shall be
included only to the extent (including size and location) specifically required. Any changes to Supplier’s existing packaging or labeling, including any artwork changes, will be paid for by Distributor. Distributor shall pay to Supplier the
non-refundable sum of $[***] for packaging, labeling, labeling content and artwork concurrently with the execution of this Agreement (the “Initial Packaging Fee”). Notwithstanding the foregoing sentence, the Initial Packaging Fee
shall be refundable in the event that Distributor terminates this Agreement during the first twelve (12) months following the Effective Date due to Supplier’s breach of this Agreement. In the event Distributor makes additional changes to
packaging, labeling, labeling content or artwork after purchase by Supplier that result in obsolescence or in the event of termination of this Agreement for any reason by Distributor, Distributor shall pay Supplier 100% of the actual cost of these
components remaining in stock. 
 (d) Shelf Life. DBMs shall have a minimum of seventy percent (70%) remaining shelf-life at time
of delivery to Distributor. 
 (e) Obsolescence. If Supplier plans to discontinue any DBM, Supplier shall provide Distributor written
notice at least 180 days in advance of the effect of such change (unless impractical for regulatory reasons, in which case such notice shall be provided immediately after the need to discontinue the DBM is determined by Supplier). 
 (f) Changes to DBM for Regulatory Reasons. Supplier shall have the right to modify the DBM as necessary to comply with changes in applicable law
or regulatory approvals. If Supplier is required to materially modify any DBM or its Specifications, Supplier shall provide Distributor written notice at least thirty (30) days in advance of the effect of such change (unless impractical for
regulatory reasons, in which case such notice shall be provided immediately after the need to materially modify the DBM or its Specifications is determined by Supplier). In the event that Supplier makes a change to the DBM in accordance with this
Section 1(f), Supplier shall provide Distributor with information on the changes, and corresponding updated guidelines and instructions for use. In addition, in the event of a recall, Supplier shall provide replacement DBM and Samples for
Distributor’s current stock, and Distributor shall return all old stock to Supplier at Supplier’s expense. 
 (g) Changes to DBM
for Other Reasons by Supplier. If Supplier desires to modify any DBM or its Specifications for reasons other than to comply with law or regulatory approvals, Supplier shall provide Distributor written notice at least thirty (30) days in
advance of the desired effect of such change and shall not implement such change unless Distributor approves of such change, such approval not to be unreasonably withheld or delayed. Approval shall be deemed given if Distributor does not respond
within fifteen (15) days after notice from Supplier. In the event that Supplier makes a change to the DBM in accordance with this Section 1(g), Supplier shall provide Distributor with information on the changes, and corresponding updated
guidelines and instructions for use. If such change renders Distributor’s stock of DBM unsaleable, as determined by Supplier in its sole discretion, Supplier shall, at Supplier’s expense, provide Distributor with replacement DBM and
Samples sufficient to replace such stock. 
  

 2 

 (h) Changes to DBM for Other Reasons by Distributor. If Distributor desires changes to be made to
the DBM or its Specifications, Distributor shall provide Supplier with written notice at least sixty (60) days in advance of the desired effect of such change. Within thirty (30) days after such notice, Supplier will approve or disapprove
such change (such approval not to be unreasonably withheld or delayed) and estimate the cost and lead times required to make such change. Supplier shall provide Distributor with written notice of its approval or disapproval, the cost to implement
such change, any resulting change in the Distribution Fees (defined below) for such DBM and the time reasonably necessary to implement such change. If such change is approved by Supplier, Distributor shall have ten (10) days to determine
whether or not it desires to proceed with such change at Distributor’s sole cost and expense. If Distributor elects to proceed with such approved change, Supplier shall promptly implement such approved change and the Distribution Fees shall be
modified accordingly. 
 (i) Samples. Supplier shall make available for acquisition by Distributor a reasonable number of samples of
non-implantable DBM, produced from bovine or human bone (at Supplier’s sole discretion) for use only for demonstration and training purposes (“Samples”). 
 (j) Inspection. Distributor shall have the right, on written notice given not less than fifteen (15) days in advance, during Supplier’s
regular business hours, to inspect Supplier’s production facilities relating to the performance of Supplier’s duties hereunder. 
  

	 	2.	Price, Orders, and Terms Of Payment. 

 (a)
Distribution Fees. Distributor shall acquire the DBMs for the amount set forth on Schedule 3, which represent Supplier’s list price for the respective DBMs discounted by [***]%) for each DBM unit delivered to Distributor (the
“Distribution Fee”) as may be amended from time to time. The Distribution Fees may be increased annually by Supplier with sixty (60) days advance notice in writing provided that such change to the Distribution Fee is the result
of Supplier increasing its list price for the respective DBM. 
 (b) Sample Fees. Distributor shall acquire Samples at the amounts for
such Samples set forth on Schedule 3, as may be amended from time to time (the “Sample Fees”). The Sample Fees may be increased by not more than [***]%) annually by Supplier with sixty (60) days advance notice in
writing. 
 (c) Minimum Acquisition Commitment. 
 (i) Distributor agrees to acquire and pay for the following minimum quantities of DBM(s) in any mix, including Samples (the “Minimum Acquisition Commitment”): 
  

			
	Calendar Year 2006:	  	$[***] minimum
	Calendar Year 2007:	  	$[***] minimum
	Calendar Year 2008:	  	$[***] minimum

  

 3 

 (ii) In the event Distributor fails to acquire the Minimum Acquisition Commitment specified above in any
Calendar Year, Supplier may (but shall not be obligated to) notify Distributor in writing of the amount of any shortfall between the Minimum Acquisition Commitment for such Calendar Year and the amount of DBM actually acquired in such Calendar Year
(the “Shortfall Amount”) and request Distributor to order and pay within forty-five (45) days of the date of the notice the amount of DBM that is at least equal to the Shortfall Amount. Following such payment, the Supplier
shall deliver to Distributor, at times and in any mix (including Samples) requested by Distributor, DBM and Samples with an aggregate value equal to such Shortfall Amount payment. If Distributor does not pay the Shortfall Amount within such
forty-five-day period, Supplier shall have the right to terminate this Agreement for cause at any time effective upon written notice to Distributor. 
 (iii) Without limiting the requirements of Sections 2(c)(i) and (ii) above, Distributor shall purchase not less than $[***] worth of DBMs each calendar month throughout Calendar Year 2006, $[***] worth of DBMs
each calendar month throughout Calendar Year 2007, and $[***] worth of DBMs each calendar month throughout Calendar Year 2008 and during any extension of the Term of this Agreement. 
 (d) Forecast and Orders. 
 (i)
Rolling Forecast. Prior to the first day of each calendar month during the Term, Distributor will provide Supplier with a three (3) month rolling forecast, by calendar month, of its anticipated quantities needed of the DBMs and Samples.
The forecast will supersede, if applicable, forecasts provided by Distributor for months previously included in the forecasts. The parties anticipate the first delivery of DBMs and Samples to occur within ninety (90) days from
Distributor’s date of delivery of camera ready artwork for labeling and packaging. 
 (ii) Commitment and Acquisition Order. The
forecast for the first calendar month in each forecast shall be a binding commitment on Distributor to acquire that quantity of DBMs and Samples (the “Commitment”). The forecast will be accompanied by an acquisition order for the
Commitment. Each acquisition order shall be in writing and set forth the names and quantities of each of the DBMs and Samples to be acquired, the delivery dates, shipping instructions and fees, delivery addresses and address to which the invoices
should be sent. No other terms or any pre-printed terms or conditions of any acquisition order shall apply. The terms and conditions of this Agreement shall govern all matters between the parties. Distributor will give Supplier an acquisition order
no less than thirty (30) days prior to the date on which the delivery is requested. 
 (iii) Initial Acquisition Order and
Forecast. The initial acquisition order shall be $[***], and shall be submitted to Supplier along with the estimated mix of DBMs and Samples and the first rolling forecast concurrently upon the signing of this 

  

 4 

 
Agreement. Distributor shall order a minimum of $[***] of DBMs and/or Samples prior to the end of Calendar Year 2006. The initial acquisition order shall be
confirmed by Distributor not later than thirty (30) days after the Effective Date. The parties anticipate the first delivery of DBMs and Samples to occur within ninety (90) days from Distributor’s date of delivery of camera ready
artwork for labeling and packaging. 
 (iv) Variances in Orders. In any forecast, the quantities for the first and second month will
not be ten percent (10%) more or less than the forecast for that month provided in the immediately previous forecast. If the variance is more than ten percent (10%) then Supplier is not obligated to supply Distributor with the amount of
DBMs or Samples in excess of the forecast provided in the immediately prior forecast for the month when the forecast becomes a Commitment. Notwithstanding the foregoing, during the first twelve (12) months after the Effective Date, the
Commitment will not be less than eighty percent (80%) of the immediately previous forecast for that month but may be up to twenty percent (20%) more than the forecast for the prior month. After that period, the Commitment will not be less
than ninety percent (90%) of the immediately previous forecast for that month but may be up to ten percent (10%) more than the forecast for the prior month. 
 (v) Variances due to Supply. Due to variances in sizes of donor lots of demineralized bone powder (“Donor Lots”), in filling any order for Distributor, including the Commitment, Supplier has
the right to deliver to Distributor a quantity of DBM or Samples that is larger or smaller than the Commitment. Regardless of the size of an Order, all DBMs representing a single Donor Lot shall be shipped together. Distributor will pay for the DBMs
and Samples actually delivered. The amount of DBMs and Samples actually delivered to Distributor will not affect the forecast or Commitment requirements if the difference is not more than ten percent (10%). In the event that shipping DBM of a single
Donor Lot results in a shipment in excess of ten percent (10%) of the Commitment, such excess shall be applied to the Commitment of the subsequent month. 
 (e) Payment Terms. All amounts are payable only in U.S. Dollars. Except as otherwise set forth under this Agreement, payments shall be due to Supplier not later than thirty (30) days from the date of
invoice. Invoices shall be issued no sooner than the date of DBM delivery. Distributor shall have no right of deduction or offset. The Distribution Fees and Sample Fees do not include shipping, handling, insurance, taxes or duties, all of which
shall be the sole obligation of Distributor. 
  

	 	3.	Delivery and Title. 

 (a) Preparation for
Shipment. All DBMs and Samples shall be handled, packaged, and shipped as required by applicable laws, rules, and regulations. They shall be suitably packed for shipment in containers adequate to insure safe arrival of the DBMs and Samples at
Distributor’s designated delivery destination, marked for shipment to the address specified in Distributor’s acquisition order or such other address as Distributor may specify in writing. Supplier shall mark all containers with necessary
shipping and handling information, acquisition order numbers and date of shipment. An itemized packing list shall accompany each shipment. 
  

 5 

 (b) Shipping Terms. All DBMs and Samples will be shipped either FOB Origin, Freight
Prepaid & Charged or FOB Origin, Freight Collect (at Supplier’s sole discretion). 
 (c) Inspection and Returns for Damage
or Defect. Distributor will inspect each shipment of DBMs and Samples for obvious damage when Distributor receives the shipment. If Distributor finds an obviously damaged or defective DBM or Sample, it will provide written notice to Supplier,
describe the damage or defect and request a return authorization form. The notice and request for return must be provided within thirty (30) days following receipt of the shipment (the day of receipt will be counted as one of the days) or the
DBMs and Samples will be deemed accepted by Distributor. If there is no notice or request for return by Distributor during the thirty-day period, or the damage or defect is due to the act or omission of Distributor, then Supplier will have no
obligation to replace the DBMs and Samples and Distributor will pay for the DBM and Samples. Supplier will pay for the shipment and insurance for the authorized return of DBMs and Samples. The only remedy available to Distributor for an obviously
damaged or defective DBM or Sample is to receive a replacement. Distributor will not receive any refunds of amounts paid or credits toward future payments to Supplier. 
  

	 	4.	Limited Warranty. 

 (a) Warranty Terms.
Supplier shall warrant the DBMs pursuant to the form of Limited Warranty generally provided in connection with the distribution of the DBMs by Supplier in effect at the time of delivery of such DBMs. A copy of the Limited Warranty in effect as of
the Effective Date is attached as Schedule 4. Supplier shall have the right to make revisions to the Limited Warranty from time to time, provided that any such revision is applicable to other private label distributors of DBMs for use in the
same Field. The revised Limited Warranty will apply only to DBMs shipped to Distributor after the change. 
 (b) Warranty From Distributor
to End-Users. Distributor shall not pass through Supplier’s Limited Warranty to End-Users of the DBMs. Distributor shall be free to establish the terms of any warranty it wishes to extend to its End-User customers. Supplier’s Limited
Warranty hereunder shall not be construed to give a right of action based on such warranty to End-User customers of Distributor. 
 (c)
Limitations. The Limited Warranty will be void and Supplier will not have any obligation to honor the Limited Warranty, or have liability for any breach of Warranty to Distributor, if DBMs are used for any use outside the Field, as defined
below, or if Distributor: (a) alters, changes or damages the DBMs or any component of the DBMs; (b) distributes, advertises or promotes the DBMs for uses outside the Field; (c) uses Marketing Materials, as defined below, not approved
by Supplier as provided in Section 6(b), (d) misrepresents the nature of the DBMs, their intended uses or scope of the Field, components, or makes any statement, representation or warranty to any person or entity regarding the DBMs that
breaches this Agreement; or (e) distributes a DBM for which it has actual knowledge of defect or damage. 
  

 6 

 (d) Destruction of DBMs In Breach of Warranty. All DBMs in breach of the Limited Warranty, shall
be, at Supplier’s option and after a reasonable opportunity for Supplier to inspect such DBMs, destroyed or returned to Supplier at Supplier’s expense. 
 (e) Disclaimer. EXCEPT FOR THE EXPRESS WARRANTIES CONTAINED IN THIS SECTION 4 AND SECTION 9, SUPPLIER MAKES NO OTHER WARRANTIES OR REPRESENTATIONS WITH RESPECT TO THE DBMS, EXPRESS OR IMPLIED, INCLUDING
ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. ALL SUCH OTHER WARRANTIES ARE HEREBY DISCLAIMED. 
 (f) No
Limitation on Indemnity. The provisions of this Section 4 are not intended to, and shall not, limit the obligations of the parties under Section 8. 
  

	 	5.	Regulatory Approvals. 

 (a) Marketing
Approval. Supplier shall be solely responsible for maintaining regulatory approval for DBMs in the U.S. Supplier will supply proof of such market approval for the U.S. to Distributor. Distributor shall be solely responsible for setting
reimbursement fees with health regulatory authorities, and for billing and for collecting fees associated with distribution of the Private Label Branded DBMs. Supplier agrees to supply to Distributor all reasonable information and documentation
necessary to obtain such reimbursement approval. All costs for obtaining the reimbursement approvals are the Distributor’s financial responsibility. 
  

	 	6.	Distribution and Marketing by Distributor. 

 (a)
Marketing Rights. Distributor shall have the right to distribute the DBMs under its respective private label, either directly or, subject to the provisions of Section 6(d), through independent representatives, distributors or
sub-distributors, anywhere in the United States of America (the “Territory”), to hospitals, surgery centers or clinics at which surgery using the DBMs is conducted, or to any licensed surgeons or other licensed healthcare professionals who
perform such surgery (“End Users”). Distributor shall distribute the DBMs to its End Users at prices and on terms Distributor determines in the exercise of its sole discretion. The DBMs shall be sold strictly for use in surgical
applications involving the human spine as approved by the U.S. Food and Drug Administration (“FDA”) or other applicable regulatory authorities (the “Field”). The DBMs shall not be sold for use outside of the Field.
Distributor acknowledges that the FDA or other applicable regulatory authorities may narrow the Field at any time. Distributor shall not sell any Samples. 
 (b) Promotion and Marketing. Distributor will market, promote, advertise and distribute the DBMs in the Field with the goal of maximizing distribution of the DBMs. All marketing, advertising, promotion and
education documentation (including training materials) used by Distributor (“Marketing Materials”) shall be technically accurate and shall comply with the requirements of this Agreement. Before Distributor uses any Marketing
Materials, Distributor shall give copies to Supplier (at least ten (10) business days before anticipated use) for the approval of Supplier solely for technical accuracy of the Marketing 

  

 7 

 
Materials. Supplier shall not withhold its consent unreasonably. If Supplier finds that any part of the Marketing Materials does not comply with the
requirements of this Agreement, it shall be reasonable for Supplier to withhold its consent. 
 (c) Training. Supplier will provide
[***]-hour initial training seminars in Irvine, California to those individuals who will be representing the DBMs on behalf of Distributor. Thereafter, Supplier will provide additional training seminars at times and places as may be agreed by the
parties. Supplier will be responsible for the costs of training seminars. Each party shall be responsible for all other costs of their own personnel, including, travel, meals, and lodging. 
 (d) Distributor Representatives. Distributor has the right to use independent representatives and distributors for the promotion, marketing,
advertising and distribution of the DBMs. Distributor shall ensure that such representatives and distributors comply with this Agreement. Distributor has full responsibility for the actions and omissions of its representatives and distributors and
an action or omission by a representative that would constitute a material breach of this Agreement by the Distributor will be treated as a material breach of this Agreement by Distributor and Supplier will have all of the remedies against
Distributor set out in this Agreement for a material breach by Distributor. 
 (e) DBM Information. Supplier has given to Distributor
data and materials which support the safety and efficacy of the DBMs. During the Term, Supplier will promptly give to Distributor complete copies of all new, revised or updated summary data, labeling and technical information, if any, developed by
Supplier for the DBM. 
 (f) Market Diligence. If Distributor becomes aware of any use of the DBMs other than by End-Users or outside
the Field, then Distributor shall: (a) notify Supplier within five (5) business days; (b) if the use outside of Field is by customers of Distributor, take commercially reasonable actions to end the unapproved use; or
(c) cooperate with and assist Supplier in any legal action that Supplier may decide to bring. 
 (g) Distributor Conduct.
Distributor will conduct all of its activities pursuant to this Agreement in compliance with all applicable laws. In addition, Distributor will not: 
 (i) modify, change or alter the DBMs or Samples. 
 (ii) promote, advertise, sell or distribute the DBMs for
any use other than in the Field. 
 (iii) make any representations, statements or warranties regarding the DBMs that are inconsistent with
any applicable regulatory approvals. 
 (h) Retained Rights. This Agreement does not grant Distributor any exclusive rights. Without
limiting any other rights of Supplier, Supplier has and retains the right to: distribute the DBM anywhere in the world; license the DBM technology to any person or entity; enter into other distribution agreements for the DBM under Supplier’s
trademarks or under a private label name other than Distributor’s trade names specified on Schedule 2. 
  

 8 

	 	7.	Reports and Recalls. 

 (a) DBM Tracing.
Distributor is responsible for tracing the DBMs sold under its Private Label Brand to all End Users of such DBMs. Supplier shall provide to Distributor the appropriate contact information to be printed on the face of the graft tracing record card
for inclusion in the DBM packaging. Distributor shall maintain the records necessary for tracing such DBMs to the consignee. Distributor shall not be required to provide Supplier with any information acquired pursuant to this Section 7(a)
except to the extent required by law or to facilitate coordination of any DBM recall. 
 (b) Problem/Complaint Notice. Distributor
will notify Supplier in writing of any complaint, suspected adverse reaction (incident or near-incidents), outcome or claim related to a DBM (a “DBM Complaint”) within forty-eight (48) hours after Distributor becomes aware of
the DBM Complaint. Supplier shall provide Distributor with a phone number to use for such notification. Supplier will investigate the facts and circumstances of the DBM Complaint in accordance with its internal procedures and applicable law and will
file any reports required in connection with the DBM Complaint with the applicable governmental agencies with jurisdiction, if any, over the DBM Complaint. Distributor will provide Supplier with all information it is able to obtain using
commercially reasonable efforts regarding the DBM Complaint including, the DBM shipped, the End-User, the history of use of the DBM by the End-User, and any other information reasonably available and necessary for the investigation by Supplier or
the completion of any governmental filing. Distributor will fully cooperate with Supplier in investigating the DBM Complaint. With the prior consent of Distributor, not to be unreasonably withheld, if necessary in order to fully investigate the DBM
Complaint, Distributor will make its employees and representatives reasonably available for interviews concerning the DBM Complaint by Supplier or its counsel and/or representatives following the reasonable request of Supplier. 
 (c) Sharing of Information. Each party shall provide the other with prompt notice if it is contacted by a Competent Authority regarding any DBM
Complaints. Supplier shall also notify Distributor of any recall of the DBM or any order for a recall by a Competent Authority. For purposes of this Section 7(c), “Competent Authority” shall mean any federal, state, or local
governmental authority or regulatory body in the United States, or any quasi-governmental or private body asserting, exercising or empowered to assert or exercise any regulatory authority thereunder and any entity or organization directly or
indirectly owned by and subject to the control of any of the foregoing. 
 (d) Recalls. Supplier shall be solely responsible for the
costs, decision and execution for a DBM recall. Distributor shall fully cooperate and reasonably assist Supplier in the event of a recall. All information obtained by Distributor will be provided as soon as reasonably possible to Supplier.

 (i) If any, or all, of the DBMs are recalled other than as a result of a wrongful act or omission of Distributor, then: 
 (1) Supplier will pay for all shipping and insurance to return the DBMs to Supplier. 
  

 9 

 (2) Within 60 days after the recall, Supplier will replace the recalled DBM(s). The only
obligations of Supplier for recalled DBM(s) are to: (A) replace the recalled DBM(s) and pay for destroying the recalled DBMs and the shipping and insurance for retrieving the recalled DBMs and shipping replacements; or (B) the obligation
specified in Subsection (c) (i) (3), below. 
 (3) Following a recall, if Supplier cannot replace the recalled DBMs
or is not able to provide Distributor with replacement DBMs for more than 60 days, then Supplier will pay to Distributor: (A) all Distribution Fees paid to Supplier by Distributor for the recalled DBMs that are not replaced; and (B) all
shipping and insurance paid by Distributor for the recalled DBMs. 
 (ii) If any, or all, of the DBMs are recalled as a result of the act or
omission of Distributor, then: 
 (1) Distributor will pay for all shipping and insurance to return the relevant DBMs to
Supplier. 
 (2) If Distributor orders DBMs to replace the recalled DBMs, then such orders will not be included in any
Forecast and will not be part of the Commitment, but will be included when calculating the Minimum Acquisition Cost. The orders will be considered additional orders and will be filled by Supplier consistent with its business commitments and
requirements. All shipping and insurance for the orders will be paid by Distributor. 
  

	 	8.	Indemnities and Insurance. 

 (a) Indemnification
by Supplier. Supplier shall indemnify, defend and hold harmless Distributor, its parent, subsidiaries and affiliates, and its and their respective officers, directors, agents and employees, and their successors and assigns, from and against any
and all claims, demands, actions, liabilities, fees, suits, causes of action, damages, penalties, recoveries and deficiencies, costs and expenses (including, without limitation, attorneys’ fees) (collectively, “Damages”) which
arise out of or relate to (i) any breach of any representation or warranty under Section 9(a), (ii) any product liability or defect arising out of, in connection with or resulting from the manufacture or supply of the DBMs,
(iii) any breach of confidentiality under Section 10, or (iv) any claim that a DBM, when used or distributed as provided for by this Agreement infringes any intellectual property rights of a third party, including but not limited to
trade secret, copyright and/or patent rights. Such indemnification shall not be limited to claims brought by third parties. 
 (b)
Indemnification by Distributor. Distributor shall indemnify, defend and hold harmless Supplier, its parent, subsidiaries and affiliates, and its and their respective officers, directors, agents and employees, and their successors and assigns,
from and against any and all Damages which arise out of or relate to (i) any breach of any representation 

  

 10 

 
or warranty under Section 9(b), (ii) any breach of confidentiality under Section 10 or (iii) any claim that a DBM, when used or
distributed in a manner instructed or suggested by Distributor that is other than as provided for by this Agreement, violates any regulatory approval related to the DBM as a result of such use or distribution or infringes any intellectual property
rights of Supplier or a third party as a result of such use or distribution, including but not limited to trade secret, copyright and/or patent rights. Such indemnification shall not be limited to claims brought by third parties. 
 (c) Insurance. Supplier represents and warrants that it is currently insured and covenants that at all times during the term of this Agreement it
will maintain a comprehensive general liability insurance policy (including products liability coverage and payment of attorneys fees coverage) with a financially sound and reputable insurer which is sufficient to adequately protect against the
risks associated with its ongoing business, including the risks which might possibly arise in connection with the transactions contemplated by this Agreement, and including without limitation, products liability insurance, with minimum coverage
amounts of $5,000,000 per occurrence and per year in the aggregate. Supplier agrees to provide Distributor a copy of its insurance policy upon request. Supplier shall have Distributor named as an additional insured beneficiary. 
  

	 	9.	Representations and Warranties. 

 (a)
Supplier. Supplier represents and warrants the following, each of which representation and warranty is true on the date of this Agreement and will be true until the end of the Term, and each of which is material and is being relied on by
Distributor: (a) it is a corporation, validly organized and existing and in good standing under the laws of the State of Washington; (b) it has full power and lawful authority to execute, deliver, and perform under this Agreement;
(c) its execution and performance of this Agreement is not contrary to, or prohibited by, any laws, or agreements to which it is a party or by which it is bound or by any arbitration award, judgment or court order by which it is bound;
(d) this Agreement, and any document executed pursuant to this Agreement, are valid obligations of Supplier enforceable in accordance with their terms; (e) it has taken all corporate action necessary in order to cause the execution and
performance of this Agreement; and (f) it has the right to manufacture and sell to Distributor for distribution and use in the Field the DBM and Samples. 
 (b) Distributor. Distributor represents and warrants the following, each of which representation and warranty is true on the date of this Agreement and will be true until the end of the Term, and each of which
is material and is being relied on by Supplier: (a) it is a corporation, validly organized and existing and in good standing under the laws of the State of California, (b) it has full power and lawful authority to execute, deliver, and
perform under this Agreement; (c) its execution and performance of this Agreement is not contrary to, or prohibited by, any laws, or agreements to which it is a party or by which it is bound or by any arbitration award, judgment or court order
by which it is bound; (d) this Agreement, and any document executed pursuant to this Agreement, are valid obligations of Distributor enforceable in accordance with their terms; (e) it has taken all action necessary in order to cause the
execution and performance of this Agreement; and (f) it has the right to use its Private Label Brands in the marketing, promotion and distribution of the DBMs. 
  

 11 

 (c) No Other Representations and Warranties. Except for the representations and warranties
contained in Sections 4 and 9, none of the parties has made any express or implied representation or warranty to the other regarding this Agreement and the subject matter of this Agreement. 
  

	 	10.	Confidentiality and Proprietary Information. 

 (a)
Confidential Information. All information designated as confidential or proprietary information, or which the other party should reasonably know is confidential, and furnished by Distributor to Supplier or any of its affiliates, or by
Supplier to Distributor or any of its affiliates, during the term of this Agreement, (“Confidential Information”) including, without limitation, any Specification, formulation, design information, DBM architecture, quality assurance
plans, marketing strategies, business plans and strategies, inventions (whether or not the subject of pending patent applications), trade secrets, know-how, cost and profit data, distribution and marketing plans, and business and financial
information, shall be kept confidential by the party receiving it. The party receiving Confidential Information shall not disclose it or make use of it, except for purposes authorized by this Agreement, nor disclose any Confidential Information to
any person or firm unless previously authorized in writing to do so; provided, however, that the receiving party may disclose it as necessary to responsible officers, employees and agents for the purposes of performing its obligations under this
Agreement, provided that such officers and employees shall have assumed in writing obligations of confidentiality no less restrictive than those contained herein The receiving party may disclose Confidential Information as required by government and
regulatory agents for the purposes of performing its obligations under this Agreement, provided that a request is made that such information be kept confidential by such government or regulatory agents. 
 (b) Exclusions. The foregoing limitations on the use and disclosure of Confidential Information shall not apply to information which: 

(i) at the time of disclosure is, or thereafter lawfully becomes, part of the public domain through no fault, act or omission of the receiving party,
its employees, agents or independent contractors; or 
 (ii) was otherwise in the receiving party’s lawful possession prior to
disclosure as shown by its written records; or 
 (iii) is subsequently rightfully obtained by the receiving party from a third party who
has the legal right to disclose it, without an obligation to keep such information confidential; or 
 (iv) is released from confidential
status by mutual agreement of the parties. 
 (c) Injunctive Relief. The receiving party acknowledges and agrees that unauthorized use
or disclosure of Confidential Information of the other party will cause serious, irreparable and significant harm, damage or loss to the other party which will be difficult or impossible to ascertain. Accordingly, the receiving party agrees that the
other party will have, in addition to all other remedies at law or in equity, the right to seek immediate injunctive relief 

  

 12 

 
to enforce the receiving party’s obligations under this Agreement. All costs, including reasonable attorneys’ fees, borne by either party in the
event of legal action shall be paid by the non-prevailing party. 
 (d) Confidentiality of Agreement. Except as required by law,
including without limitation, the rules and regulations of the U.S. Securities and Exchange Commission, Distributor and Supplier shall keep the existence and terms of this Agreement, as well as any discussions and/or materials provided in connection
herewith, strictly confidential, and shall each make all reasonable efforts to maintain such confidentiality, including restricting employees’ access to the terms of the Agreement on a “need to know” basis, limiting copies and
ensuring that all employees privy to the terms of this Agreement shall undertake in writing obligations of confidentiality no less restrictive than those contained herein. Prior to the parties exchanging any Confidential Information in connection
herewith, the parties will enter into a nondisclosure agreement in form and substance agreed upon by the parties. 
 (e) Effect of
Expiration or Termination. Upon expiration or termination of this Agreement for any reason, the receiving party shall immediately deliver to the supplying party all reproductions, copies, extract or the like of any documents or other media
containing any Confidential Information of the other party. 
 (f) Trademarks and Labeling. Distributor hereby grants to Supplier a
limited, non-exclusive, world-wide, non-transferable, royalty-free license, with the right to sublicense, solely to use the Private Label Brands, trademarks, service marks, trade names, and logos owned by or licensed to Distributor (the
“Distributor Trademarks”) in labeling and packaging the DBMs for distribution exclusively to Distributor, as directed from time to time by Distributor throughout the term of this Agreement, subject to the terms and conditions of this
Agreement. Supplier hereby agrees that the Distributor Trademarks shall only be affixed to the DBMs or other promotional materials as directed by the Distributor. Supplier shall have no rights to use the Distributor Trademarks other than for
purposes of labeling and packaging DBMs for distribution exclusively to Distributor pursuant to this Agreement or in connection with other promotional materials, which labeling and packaging or other promotional materials shall be in form and
substance satisfactory to Distributor. Supplier shall not use the Distributor Trademarks in any manner that, in Distributor’s sole and absolute discretion, may be inconsistent with Distributor’s public image or be misleading or harmful to
Distributor. Upon the termination or expiration of this Agreement, Supplier shall not have any right to supply or distribute any DBMs remaining that are labeled with any of Distributor Trademarks in any of Supplier’s inventory. 
  

	 	11.	Term and Termination. 

 (a) Term. Unless
sooner terminated in accordance with Section 11(b) below, the term of this Agreement shall commence on the Effective Date and shall terminate [***] (the “Term”). 
 (b) Early Termination for Cause. This Agreement may be terminated early for cause as otherwise provided in this Agreement, and as follows:

  

 13 

 (i) By any party immediately upon written notice if the other party is subject to any proceedings under
any federal or state law for the relief of debtors, including: the filing by or against such party of a voluntary or involuntary case under the federal bankruptcy law, which proceedings, if involuntary, are not dismissed within 30 days after their
filing; an assignment of any portion of the property of such party for the benefit of creditors; the appointment of a receiver or trustee for any portion of the assets of such party, which appointment, if obtained ex parte, is not dismissed
within 30 days thereafter; or the seizure by a sheriff, receiver, trustee in bankruptcy (or other creditors) or of any portion of the assets of such party. 
 (ii) By any party if the other party fails to perform or otherwise breaches any of its material obligations hereunder, by giving prior written notice of its intent to terminate and stating in detail the grounds for
termination. The party receiving such notice shall have thirty (30) days from the receipt of such notice to cure such material breach, at which time this Agreement shall terminate if such material breach has not been cured. In no event,
however, shall such notice of intention to terminate be deemed to waive any rights to damages or any other remedy which the party giving notice of breach may have as a consequence of such breach. 
 (iii) By any party immediately upon written notice to the other party if such party is prohibited from manufacturing, supplying or distributing the DBMs
by the FDA or other regulatory body or any applicable laws. 
 (c) Effect of Termination. If this Agreement is terminated for any
reason, (i) the parties shall be released from all further obligations, duties imposed or assumed hereunder, except as already accrued as of the termination date or as otherwise provided in this Agreement and (ii) unless otherwise required
or allowed by Supplier, in its sole discretion, Distributor must accept delivery of and pay Supplier for all orders that have been accepted by Supplier but not filled or delivered as of the effective date of the termination, and all relevant
provisions of this Agreement shall apply to such orders and the DBMs and Samples covered by such orders. Termination of this Agreement, for whatever reason, shall not affect the obligation of either party to make payments for which such party is
liable prior to such termination. In the event of any termination, Distributor shall have a [***] sell-off period during which Distributor may sell-off any of its remaining stock, provided, however, that the Agreement was not terminated due
to a breach by Distributor. All provisions that by their nature are intended to survive the termination or expiration of this Agreement, shall survive the termination or expiration, including: 2(c)(ii), 4, 7, 8(a), 8(b), 10, 11, 12 and 13 (to the
extent applicable). 
 12. Notices. All notices, requests or other communications pursuant to this Agreement shall be in writing and
addressed as follows: 
  

			
	If to Supplier:	 	IsoTis OrthoBiologics, Inc.
		 	2 Goodyear Drive
		 	Irvine, CA 92618
		 	Telephone: 949 595 8710
		 	Facsimile: 949 595 8711
		 	Attention: Chief Executive Officer
		 	cc: General Counsel

  

 14 

			
	With a copy to:	  	Latham & Watkins
		  	 650 Town Center Drive, 20th Floor
 Costa Mesa, California
92626

		  	Facsimile: 714 755 8290
		  	 Attention: Charles K. Ruck
  

		
	If to Distributor:	  	Alphatec Spine, Inc.
		  	2051 Palomar Airport Road, Suite 100
		  	Carlsbad, California 92011
		  	Telephone: 760-431-9286
		  	Facsimile: 760-431-1624
		  	 Attention: Scott Wiese
  

		
	with a copy to:	  	Heller Ehrman LLP
		  	 Time Square Tower
 7 Times Square

		  	New York, NY 10036
		  	Telephone: (212) 832-8300
		  	Facsimile: (212) 763-7600
		  	Attention: Blaine Templeman

 Any notice to be given or to be served upon any party to this Agreement will be in writing and will be deemed to
be given and received when delivered (if the notice is delivered on a day other than a business day or after 5 p.m. (local time where received) on a business day, then delivery shall be deemed to have taken place on the first business day
thereafter) to the address of each party set forth in this Section 12 via courier or other means of personal service including, but not limited to, messenger service, Fedex, DHL or United Parcel Service, or if sent by facsimile (telecopier),
when received as long as the full text of any such notice is (i) readable and (ii) is received in full prior to 5:00 p.m. (local time where received) on a business day which receipt is confirmed. If the full readable text is received
following 5:00 p.m., then the notice will be deemed received at 10:00 a.m. (local time where received) on the next succeeding business day. The telecopier number for each party is set forth in this Section 12. The notice information in this
Section may be changed by giving written notice of such change to the other party as provided in this Section for giving notice. However, unless and until such written notice of change is actually received, the last address or telecopier number as
stated by written notice or as provided in this Agreement, if no written notice of change has been sent or received, will be deemed to continue in effect for all purposes. 
  

	 	13.	General Provisions. 

 (a) Assignment. This
Agreement may not be assigned or transferred by any of the parties, and no rights or obligations hereunder may be delegated or assigned, without the express written consent of the other party. Notwithstanding the foregoing, either party may assign
or transfer this Agreement in its entirety in connection with an acquisition of all or substantially all of the assets or voting stock of such party or a merger or consolidation involving such party. 
  

 15 

 (b) Entire Agreement. This Agreement and the Schedules hereto shall constitute the entire
agreement between the parties hereto and shall supersede any other agreements, whether oral or written, express or implied, as they pertain to the supply of the DBMs by Supplier to Distributor. All distribution shall be pursuant to the terms set
forth in this Agreement. All quotations, acquisition orders, releases, authorizations, acknowledgments and invoices issued pursuant to this Agreement shall be subject to the provisions of this Agreement. The parties acknowledge that any provisions
on any such quotation, acquisition order, release, acknowledgment or invoice that conflict with the terms of this Agreement shall be deemed deleted. 
 (c) Relationship. The relationship created by this Agreement shall be strictly that of supplier and distributor as independent contractors and no agency, partnership or joint venture shall be deemed to be
created hereby. Nothing in this Agreement shall constitute one party as an agent or legal representative of any other party for any purpose whatsoever, and no party is granted no right or authority hereunder to assume or create any obligation,
express or implied, or to make any representation, warranties or guarantees, on behalf of any other party. 
 (d) Waiver. A waiver by
any party of a breach of any of the terms of this Agreement by the other party shall not be deemed a waiver of any subsequent breach of the terms of this Agreement. All waivers of any rights or obligations must be in writing and signed by the party
granting such waiver. 
 (e) Release. The expiration or termination of this Agreement for any reason whatsoever shall neither be
deemed a release, nor shall it relieve any party from any obligation under this Agreement which may have accrued prior thereto. 
 (f)
Specific Performance. The parties intend that the following obligations and provisions of this Agreement be enforceable by specific performance and other equitable relief: (a) the confidentiality provisions of Section 10 and
(b) provisions relating to the protection of intellectual property rights (collectively the “Specific Performance Provisions”). The parties acknowledge that a party seeking to enforce the Specific Performance Provisions will
not have an adequate remedy at law for the breach of the Specific Performance Provisions, damages alone will not be adequate for a breach of the Specific Performance Provisions, and such party will suffer irreparable harm as a result of such breach.
Such party shall have the right to enforce the Specific Performance Provisions through specific enforcement and all equitable remedies, including, but not limited to, mandatory and prohibitory injunctions. 
 (g) Governing Law and Jurisdiction. This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State
of California as a contract made between two parties made in California to be performed and consummated in California. In the event of any dispute, the Chief Executive Officer of each party shall meet and discuss the dispute and attempt to resolve
the dispute in good faith. The sole and exclusive venue for any action brought under this Agreement shall be in a federal or state court in Orange County, California, and the parties agree that such courts shall have jurisdiction. Unless laws or
rules strictly require different service of process, service of process may be made by certified mail return receipt requested sent to the address shown in Section 12. 
  

 16 

 (h) Severability. If any provision of this Agreement is deemed invalid or unenforceable by a court
of competent jurisdiction, such invalidity or enforceability shall not affect or limit the validity or enforceability of any other provision hereof. 
 (i) Force Majuere. No party shall be held responsible for any delay or failure in performance of any part of this Agreement to the extent such delay or failure is caused by fire, flood, strike, civil,
governmental or military authority, or act of God. When a party’s delay or nonperformance continues for a period of at least ninety (90) days due to any such event, the other party may terminate this Agreement. 
 (j) Headings. All headings and captions are inserted for convenience of reference only and shall not affect the meaning or interpretation of any
provision hereof. 
 (k) Counterparts. This Agreement may be executed in any number of counterparts, each of which once so executed
and delivered shall be deemed an original, but all of which shall constitute but one and the same Agreement. 
 (l) Amendment. No
amendment or modification relating in any manner to this Agreement shall be effective unless executed in writing and signed by the parties. 
 (m) Attorneys’ Fees. In the event of any action or claim between the parties hereto relating to the Agreement or the breach hereof, the prevailing party in such action claim shall be entitled to recover from such other party the
costs and expenses of such prevailing party, including reasonable fees of attorneys and other advisors, incurred in taking or defending such action or claim. 
 (n) No Third Party Beneficiaries. Except in connection with Sections 8(a) and 8(b), which are for the benefit of those identified therein, nothing herein is intended or shall be construed to confer upon any
person or entity, other than the parties hereto and their respective successors and assigns, any rights, remedies or other benefits under or by reason of this Agreement. 
 (o) Remedies Not Exclusive. No remedy conferred by any of the provisions of this Agreement is intended to be exclusive of any other remedy, and each and every remedy will be cumulative and will be in addition
to every other remedy given hereunder or now or hereafter existing at law or in equity or by statute or otherwise. The election of any one or more remedies will not constitute a waiver of the right to pursue other available remedies. 
 [Signature Page Follows] 
  

 17 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

  

			
	ISOTIS ORTHOBIOLOGICS, INC.
		
	By:	 	 /s/ Pieter Wolters

	Name:	 	Pieter Wolters
	Title:	 	President and Chief Executive Officer
	
	ALPHATEC SPINE, INC.
		
	By:	 	 /s/ Stephen T.D. Dixon

	Name:	 	Stephen T.D. Dixon
	Title:	 	Vice President and CFO

  

 18 

 SCHEDULES 
  

			
		
	Schedule 1	  	Specifications
		
	Schedule 2	  	Private Label Brands
		
	Schedule 3	  	Prices for DBMs and Samples
		
	Schedule 4	  	Limited Warranty

			
	 IsoTis OrthoBiologics, Inc.
	  	FPS-003
	 Confidential
	  	Eff. Date: 08-24-05
		  	Rev.: 1

 Schedule 1 
 Specifications 
 [***] 

 Schedule 2 
 Private Label Brands 
  

			
	[***]	  	[***]

 Schedule 3 
 Prices for DBMs and Samples 
 [***] 

 Schedule 4 
 Limited Warranty 
 The form of Limited Warranty in effect as of the Effective Date is as follows: 
 EACH DBM is warranted to be free from defects in workmanship and materials and to conform to its Specifications at the time of delivery. This warranty is limited to the
replacement of the DBM by IsoTis. NO OTHER WARRANTY IS GIVEN BY SUPPLIER and no representation, warranty or affirmation of any employee, contractor, agent, detailer, distributor or any other person actually or purporting to represent
Supplier, by word or action, will constitute a warranty and such word or action does not, and will not, expand or change the express warranty given in this Limited Warranty. SUPPLIER EXPRESSLY DISCLAIMS ANY OTHER EXPRESS OR IMPLIED WARRANTY OF
ANY KIND, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, WHETHER ARISING BY LAW, CUSTOM, CONDUCT, USAGE OR TRADE.Patent License Agreement

 Exhibit 10.21 
 CONFIDENTIAL TREATMENT REQUESTED 
 LICENSE AGREEMENT 
 This License Agreement is entered into and made effective as of this 23rd day of January, 2007 (the “Effective Date”), by and between SCIENT’X S.A., a company incorporated under the
laws of France, company number : Versailles B 348 366 733, having its head office located in Bâtiment Calypso- Parc Ariane 3-5 rue Alfred Kastler, 78284 Guyancourt cedex, FRANCE, represented by Mr Olivier Carli, Chairman, and hereafter called
‘SCIENT’X’, and ALPHATEC SPINE INC., a California corporation (Employer Identification Number 33-0412288) with head offices located at 2051 Palomar Airport Road, Suite 100, Carlsbad, California, U.S.A., represented by Mr. John
Foster and hereafter called “Licensee”. 
 RECITALS 
 A. SCIENT’X is engaged in the development and production of orthopaedic implants, and especially spinal implants, has a knowledge and know-how in this area, and is producing and marketing products based on the
three patents set forth in the Exhibit A hereto, all of these patents being authorised in the Territory, and hereinafter all together called the ‘Patents.’ 
 B. Licensee, is engaged in the business of the development, manufacturing, sale and marketing of spinal products and medical devices, and has experience and skills to promote the sale of the products in the Territory.
Licensee wishes to acquire from SCIENT’X the right to carry on such business. 
 C. SCIENT’X is willing to broaden the market for its products by
granting to Licensee the right for the Licensee to exploit the Patents to produce, sell, market and distribute Licensed Products in the Territory (as set forth on Exhibit B attached hereto), and Licensee wishes to acquire, such non exclusive
license in the Territory. 
 AGREEMENT 
 NOW, THEREFORE, in consideration of the mutual covenants and conditions set forth herein, SCIENT’X and Licensee hereby agree as follows: 
 1. Definitions. Capitalized terms shall have the meaning set forth below. 
 1.1 Affiliate. The term
“Affiliate” shall mean any entity which directly or indirectly controls, is controlled by or is under common control with Licensee. The term “control” as used herein means the possession of the power to direct or cause the
direction of the management and the policies of an entity, whether through the ownership of a majority of the outstanding voting securities or by contract or otherwise. 
 1.2 Medical Devices. The term “Medical Devices,” individually, or collectively, shall mean any one or more product, device, method, procedure, material, or element utilized by the surgeons, in order to
repair, cure or reinforce the patient’s spine. 
 1.3 Confidential Information. The term “Confidential Information” shall mean
any and all proprietary or confidential information of SCIENT’X or Licensee which may be 

  

 1 

 
exchanged between the parties at any time and from time to time during the term of this Agreement, including without limitation, the terms of this Agreement.
Information shall not be considered confidential to the extent that it: 
 a. is publicly disclosed through no fault of any party hereto,
either before or after it becomes known to the receiving party; or 
 b. was known to the receiving party prior to the date of this
Agreement, which knowledge was acquired independently and not from another party hereto (or such party’s employees); or 
 c. is
subsequently disclosed to the receiving party in good faith by a third party who has a right to make such disclosure; or 
 d. has been
published by a third party as a matter of right. 
 1.4 Field. The term “Field” shall mean disorders of the human spine.

 1.5 Licensed Product. The term “Licensed Product” shall mean any product which cannot be developed, manufactured, offered to
sale, used or sold without (i) infringing one or more claims under SCIENT’X Patent Rights; or (ii) utilizing any part of SCIENT’X Technology not otherwise includable within SCIENT’X Patent Rights. 
 1.6 Net Sales. The term “Net Sales” shall mean the end user gross amount received by Licensee upon payment of invoice, or its Affiliates and
sublicensees, or any of them, on all sales of Licensed Products, less (i) discounts actually allowed; (ii) credits for claims, allowances, retroactive price reductions or returned goods; (iii) prepaid freight; (iv) sales taxes or
other governmental charges actually paid in connection with sales of Licensed Products (but excluding what are commonly known as income taxes and value-added taxes); and (v) refunds or rebates actually paid. For purposes of determining Net
Sales, a sale shall be deemed to have occurred when an invoice therefore shall be generated and payment received by Licensee, or its Affiliates and sublicensees or any of them. Sales of Licensed Products by Licensee, or an Affiliate or sublicensee
of Licensee to any Affiliate or sublicensee which is a reseller thereof shall be excluded, and only the subsequent sale of such Licensed Products by Affiliates or sublicensees of Licensee to unrelated parties shall be deemed Net Sales hereunder.

 1.7 SCIENT’X Patent Rights. The term “SCIENT’X’ Patent Rights” shall mean rights arising out of or resulting from
any and all U.S. and foreign patent applications and patents, here above called, the Patents; including all provisionals, substitutions, continuations, continuations-in-part, divisionals, supplementary protection certificates, renewals, all letters
patent granted thereon, and all reissues, reexaminations, extensions, confirmations, revalidations, registrations, patents of addition thereof, PCTs and foreign counterparts, so long as said patents have not been held invalid and/or unenforceable by
a court of competent jurisdiction from which there is no appeal or, if appealable, from which no appeal has been taken. 
 1.8 SCIENT’X
Technology. The term “SCIENT’X Technology” shall mean so much of the technology specifically related to the products listed on Exhibit A attached hereto as is proprietary to SCIENT’X together with materials, information
and know-how related thereto whether or not the same is eligible for protection under the patent laws of the United States or elsewhere, and whether or not any such processes and technology, or information related thereto, would be enforceable as a
trade secret or the copying of which would be enjoined or restrained by a court as constituting unfair competition. 
  

 2 

 1.9 Control or Controlled. The term “Control” of “Controlled” shall mean with respect
to any intellectual property right, the possession by a party of the ability to grant a license or sublicense of such intellectual property as provided for herein without violating the terms of any arrangement or agreements between such party and
any third party. 
 2. License Terms and Conditions. 
 2.1 Grant of License. SCIENT’X hereby grants to Licensee a non exclusive license in the Territory, including the right to sublicense, under SCIENT’X Patent Rights as specified in Exhibit A and the SCIENT’X Technology,
to make, to have made, to import, to use, to offer for sale (including offers for sale made by Licensee’s third-party agents), and to sell (including sales made by Licensee’s third-party agents) Licensed Products in the Field, subject to
the terms of this Agreement. The parties agree that this grant of license shall not affect the rights of SCIENT’X to develop, manufacture, market and sell its products either by itself or through its distribution agents. 
 2.2 Initial License Fee. In partial consideration for the non exclusive license granted pursuant to Section 2.1 hereof, Licensee shall pay to
SCIENT’X a non-refundable license fee upon execution of this Agreement in the amount of two million euros (€2,000,000) (the “Initial License Fee”). The Initial License Fee described in this Section is consideration for the
grant and continuation of the license hereunder, and SCIENT’X shall have no obligation to return any portion of such the Initial License Fee, notwithstanding any failure by Licensee to develop any Licensed Product or market any Licensed Product
commercially, and notwithstanding the volume of sales of any such Licensed Product. 
 2.3 [***] SCIENT’X agrees that during the time
period beginning on the Effective Date and ending [***] years thereafter, that it shall not enter any into a licensing or similar transaction related to the SCIENT’X Patents on better financial terms than those set forth in this Agreement,
provided that such restriction shall not be of any force and effect in connection with or following the transfer or sale of all or substantially all of SCIENT’X’s assets or business related to this Agreement, or in the event of
SCIENT’X’s merger, consolidation, change in control or similar transaction. 
 2.4 Royalties 
 2.4.1 Percentage Royalty. In addition to the payment described in Section 2.2 above, Licensee agrees to pay Licensor during the term of this
Agreement a royalty for each Licensed Product sold by Licensee or its sublicensees (but not more than one royalty for each Licensed Product) of [***]%) of the Net Sales of Licensed Product in the Territory. 
 Licensee’s obligation to pay royalties hereunder shall cease upon the earlier of (i) the expiration of the Patents or (ii) the termination of this
Agreement (the “Royalty Term”). The Patents shall be deemed to have expired upon the non-payment of the maintenance fee, upon the judgment of invalidity or unpatentability by a court or administrative agency of competent jurisdiction from
which no appeal is taken or can be taken or upon expiration of the term of the Patents 
 At the time Licensee delivers the accounting statement required by
Section 2.9 below, Licensee shall simultaneously pay to Licensor a sum equal to the aggregate payment due based on the information contained in such accounting statement and consistent with this Agreement. 
  

 3 

 2.4.2 Minimum Royalty. Licensee shall pay to SCIENT’X, as a minimum annual royalty for the twelve
(12) month period beginning with the commencing date of this Agreement, [***]€[***][***] euros, and the amount of the minimum annual royalty payable for each of the [***] subsequent twelve (12) month periods during the term hereof
shall be [***]€[***] euros. Any percentage royalties earned and paid to SCIENT’X pursuant to Section 2.4.1 hereof for any twelve (12) month period shall be credited against the minimum royalty payable for such period, and the
payment of any shortfall between actual royalties paid and the minimum annual royalty applicable to such twelve (12) month period shall be payable to SCIENT’X within sixty (60) days after the last day of such twelve (12) month
period. 
 2.4.3 One Royalty. Only one royalty, calculated at the highest applicable royalty rate under this Section 2, shall be payable
to SCIENT’X hereunder for each sale of a Licensed Product. 
 2.5 Quarterly Payments. 
 2.5.1 Sales by Licensee. With regard to Net Sales made by Licensee or its Affiliates, royalties shall be payable by Licensee quarterly, within sixty
(60) days after the end of each calendar quarter, based upon the Net Sales of Licensed Products in the Territory during such preceding calendar quarter, commencing with the calendar quarter in which the first commercial sale of any Licensed
Product is made. 
 2.5.2 Sales by Sublicensees. With regard to Net Sales made by sublicensees- only when such sublicense are expressly
agreed by SCIENT’X of Licensee or its Affiliates, royalties shall be payable by Licensee quarterly, within ninety (90) days after the end of each calendar quarter, based upon the Net Sales of Licensed Products by such sublicensee during
such preceding calendar quarter, commencing with the calendar quarter in which the first commercial sale of any Licensed Product is made by such sublicensee. 
 2.6 Term of License. Unless terminated sooner in accordance with the provisions of this Agreement, the term of this license is [***] years and shall expire when the last of the royalty obligations set forth has
expired. 
 2.7 Sublicense. Licensee shall no grant sublicense without SCIENT’X’s prior written agreement, provided that Licensee
shall be entitled to allow its third party distribution agents to market and sell the Licensed Products without obtaining the approval of SCIENT’X. 
 2.8 Duration of Royalty Obligations. The royalty obligations of Licensee as to each Licensed Product shall terminate with the expiration of each SCIENT’X Patent Rights utilized by or in such Licensed Product,
with respect to Licensed Products not utilizing any SCIENT’X Patent Rights, [***] years after the date of first commercial sale of such Licensed Product in such country. 
 2.9 Reports. Licensee shall furnish to SCIENT’X at the same time as each royalty payment is made by Licensee, a detailed written report of Net Sales
of the Licensed Products and the royalty due and payable thereon, including a description of any offsets or credits deducted therefrom, on a product-by-product basis, for the calendar quarter upon which the royalty payment is based. 
  

 4 

 2.10 Records. Licensee shall keep, and cause its Affiliates and sublicensees to keep, full, complete and
proper records and accounts of all sales of Licensed Products in sufficient detail to enable the royalties payable on Net Sales of each Licensed Product to be determined. SCIENT’X shall have the right to appoint an independent certified public
accounting firm approved by Licensee, which approval shall not be unreasonably withheld, to audit the records of Licensee, its Affiliates and sublicensees as necessary to verify the royalties payable pursuant to this Agreement. Any auditing firm
appointed by SCIENT’X shall execute a confidentiality agreement with Licensee prior to performing such audit. Licensee, its Affiliates and sublicensees shall pay to SCIENT’X an amount equal to any additional royalties to which
SCIENT’X is entitled as disclosed by the audit, plus interest thereon at the rate of one-and-one-half percent (1.5%) per month. Such audit shall be at SCIENT’X’ expense; provided, however, that if the audit discloses that
SCIENT’X was underpaid royalties with respect to any Licensed Product by at least five percent (5%) for any calendar quarter, then Licensee, its Affiliates or sublicensee, as the case may be shall reimburse SCIENT’X for any such audit
costs. SCIENT’X may exercise its right of audit as to each of Licensee, its Affiliates or sublicensees no more frequently than once in any calendar year. The accounting firm shall disclose to SCIENT’X only information relating to the
accuracy of the royalty payments. Licensee, its Affiliates and sublicensees shall preserve and maintain all such records required for audit for a period of three (3) years after the calendar quarter to which the record applies. 
 2.11 Foreign Sales. Licensee shall not do sales out of the Territory, unless prior written agreement with SCIENT’X. 
 3. Patent Matters. 
 3.1 Patent Prosecution and Maintenance.
From and after the date of this Agreement, the provisions of this Section 3 shall control the prosecution and maintenance of any patent included within SCIENT’X Patent Rights. Subject to the requirements, limitations and conditions set
forth in this Agreement, SCIENT’X shall direct and control (i) the preparation, filing and prosecution of the United States and foreign patent applications within SCIENT’X Patent Rights (including any interferences and foreign
oppositions); and (ii) maintain the patents issuing therefrom. SCIENT’X shall select the patent attorney, subject to Licensee’s written approval, which approval shall not be unreasonably withheld. Licensee shall have full rights of
consultation with the patent attorney so selected on all matters relating to SCIENT’X Patent Rights. SCIENT’X shall use its best efforts to implement all reasonable requests made by Licensee with regard to the preparation, filing,
prosecution and/or maintenance of the patent applications and/or patents within SCIENT’X Patent Rights. In the event SCIENT’X fails to prosecute or maintain any of the SCIENT’X Patent Rights, Licensee shall have the right to control
the prosecution and maintenance of any patent included within SCIENT’X Patent Rights and all amounts spent by the Licensee in connection with such activities shall be credited against any royalty amounts that are due. 
 3.2 Information to Licensee. SCIENT’X shall keep Licensee informed with regard to the patent application and maintenance processes. SCIENT’X
shall deliver to Licensee copies of all patent applications, amendments, related correspondence, and other related matters. 
  

 5 

 3.3 Patent Costs. SCIENT’X shall pay for the patent’s costs. 
 3.4 Ownership. The patent applications filed and the patents obtained by SCIENT’X pursuant to Section 3.1 hereof shall be owned solely by
SCIENT’X, assigned to SCIENT’X and deemed a part of SCIENT’X Patent Rights. 
 3.5 Intentionally Omitted. 
 3.6 Infringement Actions. 
 3.6.1
Prosecution and Defense of Infringements. SCIENT’X shall prosecute any and all infringements of any SCIENT’X Patent Rights and shall defend all charges of third party infringement of the SCIENT’X Patent Rights. SCIENT’X may enter
into settlements, stipulated judgments or other arrangements respecting such infringement, at its own expense and without the consent of the Licensee, provided that the Licensee’s rights under this Agreement are not affected in a materially
adverse manner by such settlement, stipulated judgment or other arrangement, in which case SCIENT’X shall seek the consent of the Licensee prior to entering into such settlement, stipulated judgment or other arrangement, and Licensee shall not
unreasonably withhold such consent. Licensee agrees to provide reasonable assistance of a technical nature which SCIENT’X may require in any litigation arising in accordance with the provisions of this Section 3.6.1, for which
SCIENT’X shall pay to Licensee a reasonable hourly rate of compensation. 
 3.6.2 Allocation of Recovery. Any damages or other recovery
from an infringement action undertaken by SCIENT’X pursuant to Section 3.6.1 shall first be used to reimburse the parties for the costs and expenses incurred in such action, and shall thereafter be allocated between the parties on a pro
rata basis in proportion to the amount that each party contributed to the costs and expenses incurred in such action. . 
 4. Obligations Related to
Commercialization. 
 4.1 Licensee’s Right of First Refusal. During the term of this Agreement and for a period of six months following
the expiration or termination of this Agreement (the “ROFR Period”), if SCIENT’X makes a filing to obtain government approval for the sale or marketing in the Territory of [***] (such Medical Device shall be referred to as a
“ROFR Device”), SCIENT’X shall notify the Licensee within thirty (30) following such filing. Licensee shall have a right of first refusal (the “ROFR”) with respect to a license of the technology Controlled by
SCIENT’X that is embodied in such ROFR Device (the “ROFR Technology”) and the Licensee shall be required to provide notice to SCIENT’X within twenty (20) days following Licensee’s receipt of SCIENT’X’s
notification stating whether License is exercising its ROFR. If Licensee exercises its ROFR the parties agree to conduct good-faith negotiations for one hundred twenty (120) days from the expiration of Licensee’s twenty (20) day
response period to enter into a license agreement for to the ROFR Technology. If the parties are unable to enter into an agreement during the 120-day good-faith negotiation period, SCIENT’X shall be entitled to enter into a license, sale or
similar transfer agreement with a third party in connection with such ROFR Technology, provided that, prior to executing such agreement with such third party, SCIENT’X is required to make the identical offer to the Licensee, and the Licensee
shall have twenty (20) days to accept such offer. If the Licensee declines to exercise its ROFR or fails to provide timely notice of exercise of its ROFR, SCIENT’X shall 

  

 6 

 
have no obligations to the Licensee with respect to such ROFR Technology. It is expressly agreed that such First Refusal Right is strictly limited to [***]
and only applies to the first [***] of such [***]. 
 4.2 Governmental Approvals and Marketing of Licensed Products. Licensee shall be
responsible for obtaining all necessary governmental approvals for the development, production, distribution, sale and use of any Licensed Product, at Licensee’s expense, including, without limitation, any safety studies. Licensee shall have
sole responsibility for any warning labels, packaging and instructions as to the use of Licensed Products and for the quality control for any Licensed Product. SCIENT’X agrees to provide reasonable assistance to the Licensee, at the sole cost
and expense of the Licensee, with regards to the Licensee obtaining all necessary government approvals for the Licensed Products. 
 4.3
Indemnity. Licensee hereby agrees to indemnify, defend and hold harmless SCIENT’X and any and all co-owners of SCIENT’X Patent Rights, and any parent, subsidiary or other affiliated entity and their trustees, officers, employees,
scientists and agents from and against any liability or expense arising from any product liability claim asserted by any party as to any Licensed Product or any claims arising from the use of any SCIENT’X Patent Rights pursuant to this
Agreement. Such indemnity and defense obligation shall apply to any product liability or other claims, including without limitation, personal injury, death or property damage, made by employees, subcontractors, sublicensees, or agents of Licensee,
as well as any member of the general public. Licensee shall use its best efforts to have SCIENT’X, and any and all co-owners of SCIENT’X Technology or SCIENT’X Patent Rights, and any parent, subsidiary or other affiliated entity and
their trustees, officers, employees, scientists and agents named as additional insured parties on any product liability insurance policies maintained by Licensee, its Affiliates and sublicensees applicable to Licensed Products. SCIENT’X hereby
agrees to indemnify, defend and hold harmless Licensee and any parent from and against any liability or expense arising from any (i) material breach of this Agreement by SCIENT’X (it being understood that a breach of Section 5 shall
be limited by the specific limitations contained therein), or (ii) the gross negligence or wilful misconduct of SCIENT’X. 
 4.4
Patent Marking. To the extent required by applicable law, Licensee shall mark all Licensed Products or their containers in accordance with the applicable patent marking laws. 
 4.5 No Use of Name; Labels; Trademarks The use of the name “SCIENT’X,” or any variation thereof in connection with the advertising or sale
of Licensed Products is not permitted without SCIENT’X’s prior written approval. 
 4.6 U.S. Manufacture. To the extent required by
applicable United States laws, Licensee agrees that Licensed Products will be manufactured in the United States, or its territories, subject to such waivers as may be required, or obtained, if at all, from the United States Department of Health and
Human Services, or its designee. SCIENT’X agrees to provide reasonable assistance to the Licensee, at the sole cost and expense of the Licensee, with regards to the manufacturing the Licensed Products. 
 4.7 Foreign Registration. Licensee agrees to register this Agreement with any foreign governmental agency which requires such registration, and Licensee
shall pay all costs and legal fees in connection therewith. In addition, Licensee shall assure that all foreign laws affecting this Agreement or the sale of Licensed Products are fully satisfied. 
  

 7 

 5. Limited Warranty and Additional Covenants. 
 SCIENT’X hereby represents, warrants and covenants that (i) it is the sole owner of the SCIENT’X Patent Rights and that it has the
exclusive right to grant a license on the Patents; (ii) it has not licensed any rights to any third party for the use of the SCIENT’X Patent Rights in the Territory, nor will it do so during the [***] after the Effective Date, provided
that such [***] restriction shall not be of any force and effect in connection with or following the transfer or sale of all or substantially all of SCIENT’X’s assets or business related to this Agreement, or in the event of SCIENT’X
merger, consolidation, change in control or similar transaction (iii) it has not received notification of alleged infringement by any third party in which the validity of any of the Patents owned by SCIENT’X in the Territory are
challenged; (iv) it has not received written notification that legal proceedings have been commenced, or are expected to be commenced, in which there may be assertions of infringement by SCIENT’X, of the patents, trademarks or copyrights
of any third party in the Territory arising out of the SCIENT’X Technology; and (v) it has full right and power to enter into this Agreement. SCIENT’X AND ANY AND ALL CO-OWNERS if any, OF SCIENT’X TECHNOLOGY OR SCIENT’X
PATENT RIGHTS MAKES NO OTHER WARRANTIES CONCERNING SCIENT’X PATENT RIGHTS COVERED BY THIS AGREEMENT, INCLUDING WITHOUT LIMITATION, ANY EXPRESS OR IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE AS TO SCIENT’X PATENT
RIGHTS, SCIENT’X TECHNOLOGY OR ANY LICENSED PRODUCT. SCIENT’X AND ANY AND ALL CO-OWNERS OF SCIENT’X TECHNOLOGY OR SCIENT’X PATENT RIGHTS MAKES NO WARRANTY OR REPRESENTATION AS TO THE VALIDITY OR SCOPE OF SCIENT’X PATENT
RIGHTS, OR THAT ANY LICENSED PRODUCT WILL BE FREE FROM AN INFRINGEMENT ON PATENTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR THAT NO THIRD PARTIES ARE IN ANY WAY INFRINGING SCIENT’X PATENT RIGHTS COVERED BY THIS AGREEMENT.

 6. Interests in Intellectual Property Rights. 
 6.1 Preservation of Title. SCIENT’X and any and all co-owners of SCIENT’X Patent Rights shall retain full ownership and title to SCIENT’X Patent Rights licensed hereunder and shall preserve and maintain such full ownership
and title, subject to Licensee fully performing all of its obligations under this Agreement. 
 6.2 Royalty-free License to Improvements.
Licensee shall own all improvements to the Licensed Products it creates (the “Improvements”) to the extent that such Improvements are not contained within the SCIENT’X Patents. Licensee hereby grants to SCIENT’X a nonexclusive,
royalty-free license, sublicensable (within the limits imposed by this Section 6.2) to any Improvement, strictly for SCIENT’X’s non-commercial research purposes, with the right to sublicense such license to other non-profit
institutions for their non-commercial research purposes. 
 6.3 Governmental Interest. Licensee and SCIENT’X acknowledge that
SCIENT’X has received, and expects to continue to receive, funding from the United States Government in support of SCIENT’X’ research activities. Licensee and SCIENT’X acknowledge and agree 

  

 8 

 
that their respective rights and obligations pursuant to this Agreement shall be subject to SCIENT’X’ obligations and the rights of the United
States Government, if any, which arise or result from SCIENT’X’ receipt of research support from the United States Government, including without limitation, the grant by SCIENT’X to the United States a nonexclusive, irrevocable,
royalty-free license to SCIENT’X Technology and SCIENT’X Patent Rights licensed hereunder for governmental purposes. 
 6.4
Reservation of Rights. SCIENT’X and any and all co-owners of SCIENT’X Patent Rights reserves the right to use for any non-commercial research purposes and the right to allow other non-profit institutions to use for any non-commercial
research purposes any SCIENT’X Technology and SCIENT’X Patent Rights licensed hereunder, without SCIENT’X and any and all co-owners of SCIENT’X Technology or SCIENT’X Patent Rights or such other institutions being obligated
to pay Licensee any royalties or other compensation. 
 7. Confidentiality and Publication. 
 7.1 Treatment of Confidential Information. The parties agree that during the term of this Agreement, and for a period of three (3) years after this
Agreement terminates, a party receiving Confidential Information of the other party will (i) maintain in confidence such Confidential Information to the same extent such party maintains its own proprietary industrial information; (ii) not
disclose such Confidential Information to any third party without prior written consent of the other party; and (iii) not use such Confidential Information for any purpose except those permitted by this Agreement. 
 7.2 Publications. Licensee agrees that SCIENT’X shall have a right to publish in the Territory, in accordance with its general policies. Any
publications made by Licensee on SCIENT’X products in the Territory including but not limited to any scientific communication, done directly or indirectly through a non-commercial entity or educational meeting (such as Argos, Inspiration, etc),
or for surgery congress, shall require SCIENT’X’ prior written approval. 
 7.3 Publicity. Except as otherwise provided herein or
required by law, no party shall originate any publication, news release or other public announcement, written or oral, whether in the public press, stockholders’ reports, or otherwise, relating to this Agreement or to any sublicense hereunder,
or to the performance hereunder or any such agreements, without the prior written approval of the other party, which approval shall not be unreasonably withheld. Announcements that are required pursuant to any applicable laws, rules and regulations,
including those of applicable securities regulatory bodies, scientific publications published in accordance with Section 7.2 of this Agreement, marketing materials or similar advertisements shall not be construed as publicity governed by this
Section 7.3. 
 8. Term and Termination. 
 8.1 Term. Unless terminated sooner in accordance with the terms set forth herein, this Agreement, and the license granted hereunder, shall terminate as provided in Section 2.6 hereof. 
 8.2 Termination Upon Default. Any one or more of the following events shall constitute an event of default hereunder: (i) the failure of a party to
pay any amounts when due hereunder and the expiration of thirty (30) days after receipt of a written notice requesting 

  

 9 

 
the payment of such amount; and (ii) the failure of a party to perform any obligation required of it to be performed hereunder, and the failure to cure
within sixty (60) days after receipt of notice from the other party specifying in reasonable detail the nature of such default. Upon the occurrence of any event of default, the non defaulting party shall deliver to the defaulting party written
notice of intent to terminate, such termination to be effective upon the date set forth in such notice. 
 Such termination rights shall be
in addition to and not in substitution for any other remedies that may be available to the no defaulting party. Termination pursuant to this Section 8.2 shall not relieve the defaulting party from liability and damages to the other party for
breach of this Agreement. Waiver by either party of a single default or a succession of defaults shall not deprive such party of any right to terminate this Agreement arising by reason of any subsequent default. 
 8.3 Termination Upon Bankruptcy or Insolvency. This Agreement may be terminated by SCIENT’X giving written notice of termination to Licensee upon
the filing of bankruptcy or bankruptcy of Licensee or the appointment of a receiver of any of Licensee’s assets, or the making by Licensee of any assignment for the benefit of creditors, or the institution of any proceedings against Licensee
under any bankruptcy law, provided that in the case of any such proceeding that is involuntary, such proceeding is not terminated within one-hundred twenty (120) days thereafter. Termination shall be effective upon the date specified in such
notice. 
 8.4 Rights Upon Expiration. Neither party shall have any further rights or obligations upon the expiration of this Agreement upon
its regularly scheduled expiration date with respect to this Agreement, other than the obligation of Licensee to make any and all reports and payments for the final quarter period. Provided, however, that upon such expiration, each party shall be
required to continue to abide by its nondisclosure obligations as described in Section 7.1, and each party shall continue to abide by its obligation to indemnify the other party as described in Section 4.3. In addition, Licensee shall be
bound by its obligations under Section 6.2 hereof and SCIENT’X shall be bound by its obligations under Section 4.1 hereof. 
 8.5 Rights of Both Parties Upon Termination. Notwithstanding any other provision of this Agreement, upon any termination of this Agreement by SCIENT’X pursuant to Section 8.2 or Section 8.3 prior to the regularly scheduled
expiration date of this Agreement (i) the license granted hereunder shall terminate; (ii) except as otherwise provided in Section 8.6 of this Agreement with respect to work-in-progress, upon such termination, Licensee shall have no
further right to develop, manufacture or market any Licensed Product, or to otherwise use any SCIENT’X Patent Rights or any SCIENT’X Technology not otherwise includable therein; (iii) Licensee shall promptly return all materials,
samples, documents, information, and other materials which embody or disclose SCIENT’X Patent Rights or any SCIENT’X Technology not otherwise includable therein; provided, however, that Licensee shall not be obligated to provide
SCIENT’X with proprietary information or Improvements which Licensee can show that it independently developed. 
 8.6 Licensee Rights
Upon SCIENT’X Termination for Default. Notwithstanding any other provision of this Agreement, upon any termination of this Agreement by Licensee pursuant to Section 8.2 prior to the regularly scheduled expiration date of this Agreement:
(i) Licensee may elect to retain a fully sublicensable and transferable, fully paid up (subject to 

  

 10 

 
the remainder of this Section 8.6), non-exclusive license in the Territory under the SCIENT’X Patent Rights or any SCIENT’X Technology, to
make, to have made, to import, to use, to offer for sale, and to sell Licensed Products in the Field, subject to the terms of this Agreement; provided that, in the event Licensee so elects, Licensee shall pay, for the remainder of the Royalty Term,
a royalty equal to the royalty rate that would otherwise apply with respect to the Licensed Product hereunder. The rights and remedies of Licensee in this Section 8.6 shall be cumulative and in addition to any other rights or remedies that may
be available to the Licensee, excluding the Licensee’s right to seek repayment of the Initial License Fee in the event that the Licensee elects to use the license rights granted in this Section 8.6. 
 8.7 Work-in-Progress. Upon any such early termination of the license granted hereunder in accordance with this Agreement, Licensee shall be entitled to
finish any work-in-progress and to sell any completed inventory of a Licensed Product covered by such license which remain on hand as of the date of the termination, so long as Licensee pays to SCIENT’X the royalties applicable to said
subsequent sales in accordance with the terms and conditions as set forth in this Agreement, provided that no such sales shall be permitted after the expiration of twelve (12) months after the date of termination. 
 9. Purchase of SCIENT’X Products. 
 9.1 SCIENT’X
Product Order. SCIENT’X agrees to sell and deliver to Licensee the SCIENT’X products listed on Exhibit C in the quantities and with the order dates specified thereon (the “SCIENT’X Product Order”). The per unit price
for the SCIENT’X Product Order shall be equal to [***]. 
 9.2 Regulatory Requirements. SCIENT’X shall be responsible for packaging
of all SX products for commercial sale, including compliance with any regulatory related labelling and packaging requirements. Licensee shall have the identical rights to sell such SCIENT’X products as the Licensee shall have to sell the
Licensed Products, provided that the Licensee shall be responsible to ensure that the SCIENT’X products, once properly labelled and packaged by SCIENT’X, are marketed, distributed and sold in compliance with all applicable regulatory laws.
Licensee may reject any portion of any shipment of SCIENT’X products which is not conforming to the then-current specifications published by SCIENT’X therefor, or is misbranded or exhibits any other packaging defects. SCIENT’X
warrants that to its knowledge: (i) the SCIENT’X products do not and will not infringe or constitute a misappropriation of any third party rights (including any patents, copyrights or trade secrets) anywhere in the Territory,
(ii) there have been no adverse events caused by or contributed to by the SCIENT’X products, and (iii) the SCIENT’X products are and will be designed, manufactured, stored and shipped in compliance with all applicable laws,
including the United States Food and Drug Administration’s current good manufacturing practices and quality system regulations. 
 9.3
Delivery Terms. Title and risk of loss for the shipped SCIENT’X products shall pass to Licensee upon delivery to the Licensee’s designated delivery location. 
 9.4 Payment Terms. In connection with the SCIENT’X products purchased pursuant to this Section 9, Licensee shall pay to Licensor (i) as consideration for the delivery of the SCIENT’X Product Order,
the purchase price for the SCIENT’X products delivered within sixty (60) days of receipt of such SCIENT’X products; and (ii) as consideration for the 

  

 11 

 
right to sell, and distribute the SCIENT’X products in the Territory, the royalty obligation set forth in Section 2.4 upon the final end-use sale
of such SCIENT’X products. For the purposes of clarity, the parties agree that the purchase price for SCIENT’X products set forth in Section 9.1 shall be paid in addition to the payment of the royalty payments set forth in
Section 2.4 upon the final end-user sale of such SCIENT’X products. 
 9.5 Training. SCIENT’X agrees to provide reasonable
assistance to the Licensee, at the sole cost and expense of the Licensee, with regards to the Licensee training its sales, clinical education and marketing departments on the use of the Licensed Products, including without limitation, using
reasonable efforts to provide a surgeon champion to demonstrate the use of the SCIENT’X products in a clinical setting designated by the Licensee no less than three times in the first year following the Effective Date. 
 10. Assignment; Successors. 
 10.1 Assignment. Any and all
assignments of this Agreement or any rights granted hereunder by Licensee are void except (i) to an Affiliate of Licensee; (ii) in connection with the transfer or sale of all or substantially all of a party’s assets or business
related to this Agreement, or in the event of its merger, consolidation, change in control or similar transaction; or (iii) as expressly permitted hereunder, without the prior written consent of SCIENT’X not be unreasonably withheld.

 10.2 Binding Upon Successors and Assigns. Subject to the limitations on assignment herein, this Agreement shall be binding upon and inure
to the benefit of any successors in interest and assigns of SCIENT’X and Licensee. Any such successor or assignee of Licensee’s interest shall expressly assume in writing the performance of all the terms and conditions of this Agreement to
be performed by Licensee. 
 11. General Provisions. 
 11.1 Independent Contractors. The relationship between SCIENT’X and Licensee is that of independent contractors. SCIENT’X and Licensee are not joint venturers, partners, principal and agent, master and servant, employer or
employee, and have no other relationship other than independent contracting parties. SCIENT’X and Licensee shall have no power to bind or obligate each other in any manner, other than as is expressly set forth in this Agreement. 
 11.2 Jurisdiction, Applicable Laws and Dispute Resolution. This Agreement merges and supersedes all prior Agreements between the parties hereto. Any
controversy or claim arising out of or relating to this Agreement, or the breach thereof, shall be settled by and shall be governed by, and construed in accordance with, the laws of Switzerland, provided that the laws if the United States shall
govern any controversy or claim involving (i) the validity of the Patents; or (ii) the matters described in Section 11.9. The language of the Agreement is English. Any dispute, controversy or claim initiated by either party arising
out of, resulting from or relating to this Agreement, or the performance by either party of its obligations under this Agreement (other than bona fide third party actions or proceedings filed or instituted in an action or proceeding by a third party
against a party, or any dispute as to the scope or validity of the licensed SCIENT’X Patent Rights), whether before or after termination of this Agreement, shall be finally resolved by binding arbitration. Whenever a party shall decide to
institute arbitration proceedings, it shall give written notice to that effect to the other party. 

  

 12 

 
Any such arbitration shall be conducted under the Commercial Arbitration Rules of the UNCITRAL by a panel of three arbitrators appointed in accordance with
such rules. Any such arbitration shall be held in Geneva Switzerland. The arbitrators shall have the authority to grant injunctions and/or specific performance and to allocate between the parties the costs of arbitration in such equitable manner as
they determine. Judgment upon the award so rendered may be entered in any court having jurisdiction or application may be made to such court for judicial acceptance of any award and an order of enforcement, as the case may be. In no event shall a
demand for arbitration be made after the date when institution of a legal or equitable proceeding based upon such claim, dispute or other matter in question would be barred by the applicable statute of limitations 
 11.3. Confidentiality. Except as set forth below, the parties shall keep confidential the fact of the arbitration, the dispute being arbitrated, and the
decision of the arbitrators. Notwithstanding the foregoing, the parties may disclose information about the arbitration to persons who have a need to know, such as directors, trustees, management employees, witnesses, experts, investors, attorneys,
lenders, insurers, and others who may be directly affected. Additionally, if a party has stock which is publicly traded, the party may make such disclosures as are required by applicable securities laws. Further, if a party is expressly asked by a
third party about the dispute or the arbitration, the party may disclose and acknowledge in general and limited terms that there is a dispute with the other party which is being (or has been) arbitrated. Once the arbitration award has become final,
if the arbitration award is not promptly satisfied, then these confidentiality provisions shall no longer be applicable. 
 11.4 Entire
Agreement; Modification. This Agreement sets forth the entire agreement and understanding between the parties as to the subject matter hereof. There shall be no amendments or modifications to this Agreement, except by a written document which is
signed by both parties. 
 11.5 Headings. The headings for each article and section in this Agreement have been inserted for convenience of
reference only and are not intended to limit or expand on the meaning of the language contained in the particular article or section. 
 11.6
Severability. Should any one or more of the provisions of this Agreement be held invalid or unenforceable by a court of competent jurisdiction, it shall be considered severed from this Agreement and shall not serve to invalidate the remaining
provisions thereof. The parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by them when entering this Agreement may be realized. 

11.7 No Waiver. Any delay in enforcing a party’s rights under this Agreement or any waiver as to a particular default or other matter shall not
constitute a waiver of such party’s rights to the future enforcement of its rights under this Agreement, excepting only as to an express written and signed waiver as to a particular matter for a particular period of time. 
 11.8 Name. Whenever there has been an assignment or a sublicense by Licensee as permitted by this Agreement, the term “Licensee” as used in
this Agreement shall also include and refer to, if appropriate, such assignee or sublicensee. 
 11.9 U.S. Bankruptcy Code. All licenses
granted under this Agreement are deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of right to 

  

 13 

 
“intellectual property” as defined in Section 101 of such Code. The parties agree that Licensee may fully exercise all of its rights and
elections under the U.S. Bankruptcy Code, regardless of whether SCIENT’X files for bankruptcy in the United States or other jurisdiction. The parties further agree that, in the event Licensee elects to retain its rights as a licensee under such
Code, Licensee shall be entitled to complete access to any technology licensed to it hereunder and all embodiments of such technology. Such embodiments of the technology shall be delivered to Licensee not later than: (i) the commencement of
bankruptcy proceedings against SCIENT’X, upon written request, unless SCIENT’X elects to perform its obligations under the Agreement, or (ii) upon the rejection of this Agreement by or on behalf of SCIENT’X, upon written request.

 11.10 Further Assurances. Each party agrees to execute, acknowledge and deliver such further instructions, and to do all such other acts,
as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 11.11 Notices. Any notices required by
this Agreement shall be in writing, shall specifically refer to this Agreement and shall be sent by registered or certified airmail, postage prepaid, or by telefax, e-mail, or by overnight courier, postage prepaid and shall be forwarded to the
respective addresses set forth below unless subsequently changed by written notice to the other party: 
 Notice shall be deemed delivered
upon the earlier of (i) when received; (ii) three (3) days after deposit into the mail; (iii) the date notice is sent via both recorded telefax, and e-mail; or (iv) the day immediately following delivery to overnight courier
(except Sunday and holidays). 
 [Signature Page Follows] 
  

 14 

 IN WITNESS WHEREOF, the parties have executed this Agreement by their duly authorized representatives as
of the date set forth above 
  

			
	 SCIENT’X S.A.

		
	 By:
	 	 /s/ Olivier Carli

	 Name:
	 	Olivier Carli
	 Title:
	 	Chairman
	
	ALPHATEC SPINE, INC.
		
	By:	 	 /s/ M. Ross Simmonds

	Name:	 	M. Ross Simmonds
	Title:	 	Senior Vice President and COO

  

 15 

 EXHIBIT A 
 SCIENT’X PATENTS 
 Such SCIENT’X Patent Rights Controlled by SCIENT’X pertinent to the SCIENT’X
“Isolock” product, an implantable intervertebral connector device, including, all derivative patent applications. 
 Such SCIENT’X Patent
Rights Controlled by SCIENT’X pertinent to the SCIENT’X “Dynamic Rod” product, an implantable intervertebral connector device for intervertebral linkage with multidirectional controlled displacement, including, all derivative
patent applications. 
 Such SCIENT’X Patent Rights Controlled by SCIENT’X pertinent to the SCIENT’X “Aladyn” product, a dynamic
device, including, without limitation, all derivative patent applications. 
  

 16 

 EXHIBIT B 
 TERRITORY 
 [***] 
 [***]

 [***] 
  

 17 

 EXHIBIT C 
 SCIENT’X Products 
  

					
	 Product Name
	  	Quantity Ordered	  	Date of Order

 [***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}]]